GLP1R and obesity due to melanocortin 4 receptor deficiency: Tirzepatide, a combination of GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonist, recently approved for obesity, has demonstrated superior efficacy in weight and glucose reduction compared to GLP‐1 RAs alone.11, 12